Literature DB >> 16421096

Humanized beta-thalassemia mouse model containing the common IVSI-110 splicing mutation.

Jim Vadolas1, Mikhail Nefedov, Hady Wardan, Sima Mansooriderakshan, Lucille Voullaire, Duangporn Jamsai, Robert Williamson, Panayiotis A Ioannou.   

Abstract

Splicing mutations are common causes of beta-thalassemia. Some splicing mutations permit normal splicing as well as aberrant splicing, which can give a reduced level of normal beta-globin synthesis causing mild disease (thalassemia intermedia). For other mutations, normal splicing is reduced to low levels, and patients are transfusion-dependent when homozygous for the disease. The development of therapies for beta-thalassemia will require suitable mouse models for preclinical studies. In this study, we report the generation of a humanized mouse model carrying the common IVSI-110 splicing mutation on a BAC including the human beta-globin ((hu)beta-globin) locus. We examined heterozygous murine beta-globin knock-out mice ((mu)beta(th-3/+)) carrying either the IVSI-110 or the normal (hu)beta-globin locus. Our results show a 90% decrease in (hu)beta-globin chain synthesis in the IVSI-110 mouse model compared with the mouse model carrying the normal (hu)beta-globin locus. This notable difference is attributed to aberrant splicing. The humanized IVSI-110 mouse model accurately recapitulates the splicing defect found in comparable beta-thalassemia patients. This mouse model is available as a platform for testing strategies for the restoration of normal splicing.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16421096     DOI: 10.1074/jbc.M512931200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

Review 1.  Use of mouse models to study the mechanisms and consequences of RBC clearance.

Authors:  E A Hod; S A Arinsburg; R O Francis; J E Hendrickson; J C Zimring; S L Spitalnik
Journal:  Vox Sang       Date:  2010-03-21       Impact factor: 2.144

Review 2.  RNA Splicing and Disease: Animal Models to Therapies.

Authors:  Matías Montes; Brianne L Sanford; Daniel F Comiskey; Dawn S Chandler
Journal:  Trends Genet       Date:  2018-11-19       Impact factor: 11.639

3.  Short-hairpin RNA against aberrant HBBIVSI-110(G>A) mRNA restores β-globin levels in a novel cell model and acts as mono- and combination therapy for β-thalassemia in primary hematopoietic stem cells.

Authors:  Petros Patsali; Panayiota Papasavva; Coralea Stephanou; Soteroulla Christou; Maria Sitarou; Michael N Antoniou; Carsten W Lederer; Marina Kleanthous
Journal:  Haematologica       Date:  2018-04-26       Impact factor: 9.941

4.  Humanized Mouse Model of Cooley's Anemia.

Authors:  Yongliang Huo; Sean C McConnell; Shan-Run Liu; Rui Yang; Ting-Ting Zhang; Chiao-Wang Sun; Li-Chen Wu; Thomas M Ryan
Journal:  J Biol Chem       Date:  2008-12-19       Impact factor: 5.157

Review 5.  Animal Models of Normal and Disturbed Iron and Copper Metabolism.

Authors:  Xiaoyu Wang; Michael D Garrick; James F Collins
Journal:  J Nutr       Date:  2019-12-01       Impact factor: 4.798

6.  Preclinical transfusion-dependent humanized mouse model of beta thalassemia major.

Authors:  Yongliang Huo; Sean C McConnell; Thomas M Ryan
Journal:  Blood       Date:  2009-03-03       Impact factor: 22.113

7.  Co-transcriptional splicing regulates 3' end cleavage during mammalian erythropoiesis.

Authors:  Kirsten A Reimer; Claudia A Mimoso; Karen Adelman; Karla M Neugebauer
Journal:  Mol Cell       Date:  2021-01-12       Impact factor: 17.970

Review 8.  Recent trends in the gene therapy of β-thalassemia.

Authors:  Alessia Finotti; Laura Breda; Carsten W Lederer; Nicoletta Bianchi; Cristina Zuccato; Marina Kleanthous; Stefano Rivella; Roberto Gambari
Journal:  J Blood Med       Date:  2015-02-19

9.  Generation and Characterization of a Transgenic Mouse Carrying a Functional Human β -Globin Gene with the IVSI-6 Thalassemia Mutation.

Authors:  Giulia Breveglieri; Irene Mancini; Nicoletta Bianchi; Ilaria Lampronti; Francesca Salvatori; Enrica Fabbri; Cristina Zuccato; Lucia C Cosenza; Giulia Montagner; Monica Borgatti; Fiorella Altruda; Sharmila Fagoonee; Gianni Carandina; Michele Rubini; Vincenzo Aiello; Laura Breda; Stefano Rivella; Roberto Gambari; Alessia Finotti
Journal:  Biomed Res Int       Date:  2015-05-04       Impact factor: 3.411

10.  Unexpected CEP290 mRNA splicing in a humanized knock-in mouse model for Leber congenital amaurosis.

Authors:  Alejandro Garanto; Sylvia E C van Beersum; Theo A Peters; Ronald Roepman; Frans P M Cremers; Rob W J Collin
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.